Workflow
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of 0.9pershareversustheZacksConsensusEstimateofalossof0.9 per share versus the Zacks Consensus Estimate of a loss of 0.71. This compares to a loss of 0.82pershareayearago.Thesefiguresareadjustedfornonrecurringitems.Thisquarterlyreportrepresentsanearningssurpriseof26.760.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -26.76%. A quarter ago, it was expected that this company would post a loss of 0.83 per share when it actually produced a loss of $0.95, delivering a surprise of -14.46%.Over the last four quarters, the company ...